文献速递胸部肿瘤

AdvanTIG-302:Ociperlimab联合替雷利珠单抗对比帕博利珠单抗一线治疗PD-L1≥50%晚期NSCLC的3期研究

AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or More.
PubMed 文献 · J Thorac Oncol · 2026-07-14

AdvanTIG-302是一项3期随机研究,入组662例PD-L1表达≥50%的III/IV期NSCLC初治患者,按5:5:2随机接受Ociperlimab联合替雷利珠单抗、帕博利珠单抗或替雷利珠单抗治疗。预设中期分析因无效而终止,疗效分析仅作描述性报告;联合组中位OS为31.9个月,帕博利珠单抗组为29.4个月,分层HR为0.97(95%CI 0.76-1.23),OS无改善。

要点

  • 预设中期分析因无效终止,A组与B组OS无改善,HR 0.97(95%CI 0.76-1.23)
  • A组中位OS 31.9个月,B组29.4个月,C组27.7个月,三组间中位OS相近
  • A组中位PFS 14.3个月、ORR 61.0%;B组中位PFS 10.5个月、ORR 48.8%;安全性三组均可耐受

核心结论

  • Ociperlimab联合替雷利珠单抗较帕博利珠单抗未改善OS,各治疗组中位OS相近。
  • B组与C组比较因属描述性分析,需谨慎解读。
  • 所有治疗组安全性均可耐受,未见新的安全信号。

研究设计与样本

  • AdvanTIG-302为3期随机对照研究,纳入初治III/IV期NSCLC且PD-L1表达≥50%的患者。
  • 患者按5:5:2随机分配至A组(Ociperlimab联合替雷利珠单抗)、B组(帕博利珠单抗)或C组(替雷利珠单抗)。
  • 主要终点为A组对比B组的总生存期,关键次要分析包括无进展生存期和客观缓解率。
  • 截至2025年5月30日,预设中期分析共纳入662例患者,因无效而终止,疗效分析仅作描述性报告。

主要发现

  • A、B、C三组中位OS分别为31.9(25.7-NE)、29.4(25.8-35.0)、27.7(20.0-NE)个月。
  • A组对比B组的OS分层HR为0.97(95%CI 0.76-1.23)。
  • A、B、C三组中位PFS分别为14.3(11.5-16.0)、10.5(8.4-12.6)、16.6(8.9-26.3)个月。
  • A、B、C三组ORR分别为61.0%(55.1-66.7)、48.8%(42.9-54.7)、55.7%(44.7-66.3)。
  • A、B、C三组治疗相关不良事件发生率分别为84.3%、79.4%、79.3%。

关键数值与推荐

  • 主要终点A组对比B组的OS分层HR为0.97(95%CI 0.76-1.23)。
  • A、B、C三组中位OS分别为31.9、29.4、27.7个月。
  • A、B、C三组中位PFS分别为14.3、10.5、16.6个月。
  • A、B、C三组ORR分别为61.0%、48.8%、55.7%。
  • A、B、C三组治疗相关不良事件发生率分别为84.3%、79.4%、79.3%。

临床怎么用

  • 本研究提示在PD-L1≥50%的晚期NSCLC一线治疗中,Ociperlimab联合替雷利珠单抗未优于帕博利珠单抗,不支持以此联合方案替代标准PD-1单药治疗。
  • 因中期分析因无效终止且疗效为描述性,结果仅可供理解抗TIGIT联合抗PD-1在该人群中的疗效参考。

局限性

  • 预设中期分析因无效而终止,疗效分析仅作描述性报告,未提供正式统计学比较。
  • B组与C组的比较属描述性分析,需谨慎解读。
  • 摘要未报告研究入组地域、随访时长及亚组分析等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Novel agents that improve outcomes in NSCLC are needed. Co-inhibition of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitor motif domains and programmed cell death protein 1 (PD-1) may enhance anti-PD-1 activity. AdvanTIG-302 is a phase 3 trial of ociperlimab plus tislelizumab (A), pembrolizumab (B), and tislelizumab (C) in first-line stage III/IV NSCLC with programmed cell death-ligand 1 expression of 50% or more (NCT04746924). METHODS: Eligible patients were randomized (5:5:2) to A, B, or C. The primary objective was overall survival (OS) in A versus B; key secondary analyses were progression-free survival (PFS) and overall response rate (ORR). RESULTS: As of May 30, 2025, the prespecified interim analysis (N = 662) was terminated due to futility; efficacy analyses are descriptive only. Median OS (95% confidence interval [CI]) was 31.9 (25.7-not estimable [NE]), 29.4 (25.8-35.0), and 27.7 (20.0-NE) months for arms A, B, and C, respectively; the stratified hazard ratio for A versus B was 0.97 (95% CI: 0.76-1.23). For A, B, and C, median PFS (95% CI) was 14.3 (11.5-16.0), 10.5 (8.4-12.6), and 16.6 (8.9-26.3) months and ORR (95% CI) was 61.0% (55.1-66.7), 48.8% (42.9-54.7), and 55.7% (44.7-66.3), respectively. In arms A, B, and C, treatment-related adverse events occurred in 84.3%, 79.4%, and 79.3% of patients, respectively. CONCLUSION: Ociperlimab plus tislelizumab had no improvement in OS compared with pembrolizumab; median OS was comparable across arms. Data for B versus C should be interpreted cautiously given the descriptive nature of this comparison. The safety profiles of all treatment arms were well tolerated, with no new safety signals.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Socinski MA, Reck M, Paz-Ares L, et al. AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or More. J Thorac Oncol. 2026. PMID: 42448175. doi:10.1016/j.jtho.2026.104089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。